human clinical trial News
-
New Corporate Identity For Feldan Therapeutics
Feldan Therapeutics is proud to unveil its new corporate identity! This new visual highlights the company's commitment to the therapeutic development of the Feldan Shuttle technology, an innovation developed in-house by Feldan's scientists. The company's initial focus, which was the production and sale of recombinant proteins, was gradually put aside to fully concentrate efforts on the ...
-
Carina Biotech inaugural symposium to be held on 18 May 2022 in Adelaide and virtually
Please Join Us on Wednesday, 18 May 2022 9:30 am – 5:00 pm for Carina Biotech’s inaugural symposium Join us in Adelaide at the Hotel Grand Chancellor and virtually for Carina Biotech’s inaugural symposium showcasing our LGR5 CAR-T programand path to the clinic. Also hear from invited guests in the CAR-T cell therapy field who will share their latest research. RSVP to ...
-
Adiposs receives endorsement to proceed to Clinical Trials
We are thrilled to announce that following the scientific advice meeting with The Medicines and Healthcare products Regulatory Agency in the UK, Adiposs received endorsement for its flagship product, ImageBAT, to proceed to Clinical Trials. ImageBAT is the state-of-the-art imaging product that makes brown adipose tissue visible with a fast and pain-free CT scan. It enables early detection ...
By Adiposs
-
Vybion`s Huntington Drug Neutralizes Critical Disease Driver
Vybion will present data on how its drug, INT41, alters a critical event in the development of Huntington's disease at the 7th Neurodegenerative Conditions Research & Development Conference in Boston on September 9-10, 2013. INT41 is an Intrabody drug delivered by Gene Therapy that blocks gene dysregulation in Huntington's Disease by neutralizing a toxic fragment of the Huntingtin mutant ...
By Vybion
-
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis. London, 11 February 2020 - This significant milestone sees a best in class, novel multi-target drug developed ...
By Benevolent
-
Cytex Awarded CRP Award for First-In-Human Pilot Trial
Cytex is thrilled to announce the receipt of a Commercialization Readiness Pilot Program Award from the National Institute of Health entitled “Cartilage Regeneration with Tunable Inflammation Resistance.” The goal of this project is to prepare for and then conduct a First-In-Human pilot clinical trial that will test the safety of Cytex’s innovative hip implant. Cytex is ...
-
Cytex Awarded CRP Award for First-In-Human Pilot Trial
Cytex is thrilled to announce the receipt of a Commercialization Readiness Pilot Program Award from the National Institute of Health entitled “Cartilage Regeneration with Tunable Inflammation Resistance.” The goal of this project is to prepare for and then conduct a First-In-Human pilot clinical trial that will test the safety of Cytex’s innovative hip implant. Cytex is ...
-
ZetaMet™ Receives Breakthrough Device Designation from U.S. Food and Drug Administration (FDA) for Treatment of Metastatic Bone Cancers
The technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone Zetagen Therapeutics is developing the therapy for patients living with metastatic bone lesions and other osteologic conditions The Company is targeting its first human clinical trial for metastatic bone lesions to begin in early 2022 Zetagen Therapeutics, a private, ...
-
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress on June 25, 2022
Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Stephen A. Harrison, Medical Director, Pinnacle Clinical Research, will present the results of Altimmune’s recently completed Phase 1, first-in-human clinical trial of pemvidutide in an oral presentation at the European Association for the Study of the Liver (EASL) International Liver ...
-
Imaxio announces the publication of the results of a phase I trial of MVA85A-IMX313, the first human clinical trial using the IMX313 technology
Imaxio, a biotech company specialized in immunology, announces today that the results of its tuberculosis vaccine phase I clinical trial have been published in the journal Vaccine. The trial, which was conducted by the Jenner Institute at Oxford University (UK), has proved that the vaccine candidate (and thus IMX313, Imaxio’s antigen re-engineering technology) is safe in humans. The study ...
By IMAXIO S.A.
-
Adiposs raises CHF 1.8M Pre-Series a Funding led by Privilège Ventures to start Clinical Trials and Product Industrialization
GENEVA, SWITZERLAND – DECEMBER 24, 2021 – Adiposs SA, the developer of a unique diagnostic product for the non-invasive early detection of body wasting-cachexia, announced a CHF 1.8M first closing of its Pre-Series A round. The round was led by Privilège Ventures, a Swiss-based venture capital firm focused on seed and early-stage investments. Other investors include ...
By Adiposs
-
Instylla First-In-Human Clinical Trial Published Results Demonstrate Technical Success and Persistent Embolization Across All Patients
Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the publication of results[i] from the first-in-human clinical trial of Embrace™ Hydrogel Embolic System (HES) for the treatment of hypervascular tumors, in the Journal of Vascular and Interventional Radiology (JVIR). This prospective, single-arm ...
-
MODAG Initiates First-in-Patient Phase 1b Trial for Anle138b in Parkinson´s Disease
MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, today announced the clinical trial initiation of a first-in-patient Phase 1b study for anle138b in patients with mild to moderate Parkinson´s Disease (PD). Anle138b is a disease-modifying treatment option for synucleinopathies, such as Multiple ...
By MODAG GmbH
-
Leo Lens Pharma Excited to Have Its Lead Asset Ready for Human Clinical Evaluation
SAN DIEGO, CA, USA (BUSINESS WIRE June 23, 2020) – Today, Leo Lens Pharma, an emerging San Diego-based pharmaceutical company focused on helping protect sight, is pleased to announce that its lead asset, LL- BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for one ...
-
Amyris Completes First Major License For Leading RNA Vaccine Advancing Technology To Human Trials
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that it has signed an exclusive license with Nant Africa, LLC relating to the development and use of the RNA COVID vaccine Amyris developed in coordination with the Infectious ...
-
Male Contraceptive Initiative Invests SI Million in Contraline
RICHMOND, VA – October 26, 2020 – The Virginia Catalyst, formerly known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2.1 million in grants to three life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with significant matching funds from partner companies, were awarded as Round 11 of ...
-
Major Biomedical Catalyst grant win
£1 million grant will support first-in-human clinical trials of H-Guard Invizius Limited ("Invizius"), a biotechnology company developing treatments to suppress unwanted innate immune responses, today announces that it has been awarded a £1 million grant to bring H-Guard, its proprietary priming solution, designed to reduce the life-threatening inflammatory effects of ...
-
First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients
Biolojic uses its proprietary AI platform to design antibodies with new capabilities to cure disease, ushering in a new era of smart therapeutics Biolojic Tel Aviv to focus on computational design of antibodies; Boston location will focus on drug development Biolojic Design, a unique technology company pioneering computational design of human antibodies to develop smart therapeutic ...
-
Zetagen Therapeutics, Inc. Receives Patent for Regulation of Bone Growth and Bone Degradation Using Small-Molecule
U.S.-based biopharmaceutical company has discovered and patented a novel molecular pathway intended to treat metastatic bone lesions Latest patent issuance follows previous patents for methods in stimulating bone growth using ZetaMet™ New patent further enhances the Company’s Global IP strategy Zetagen Therapeutics, Inc., a private, US-based biotechnology company dedicated to ...
-
Virginia Catalyst Awards Contraline S600,000 for Clinical Translation
RICHMOND, VA – October 26, 2020 – The Virginia Catalyst, formerly known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $2.1 million in grants to three life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with significant matching funds from partner companies, were awarded as Round 11 of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you